Saltar al contenido
Merck

Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins.

Journal of medicinal chemistry (2011-05-13)
Shinji Kamisuki, Takashi Shirakawa, Akira Kugimiya, Lutfi Abu-Elheiga, Hea-Young Park Choo, Kohei Yamada, Hiroki Shimogawa, Salih J Wakil, Motonari Uesugi
RESUMEN

Fatostatin, a recently discovered small molecule that inhibits activation of sterol regulatory element-binding protein (SREBP), blocks biosynthesis and accumulation of fat in obese mice. We synthesized and evaluated a series of fatostatin derivatives. Our structure-activity relationships led to the identification of N-(4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)methanesulfonamide (24, FGH10019) as the most potent druglike molecule among the analogues tested. Compound 24 has high aqueous solubility and membrane permeability and may serve as a seed molecule for further development.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
25-Hydroxycholesterol, ≥98%
Supelco
Warfarina, PESTANAL®, analytical standard
Supelco
Warfarina, analytical standard